Journals / Türkderm-Deri Hastalıkları ve Frengi Arşivi / 2008 / Cilt: 42 - Sayı: 1

Oral mirtazapine in persistent chronic urticaria

Tedaviye dirençli kronik ürtikerde oral mirtazapin

Pages
31–33
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Herein we present three cases responding oral mirtazapine, resistant combination therapies including antihistaminics, leucotrien antagonists and systemic corticosteroids.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Chronic urticaria accounts for up to 75% of patients with urticaria attending dermatology clinics and can persist for many years.
📊
Key Findings & Data:Chronic urticaria often causes significant quality of life issues due to pruritus and urticarial lesions resistant to treatment.
💡
Conclusion & Impact:Herein we present three cases responding oral mirtazapine, resistant combination therapies including antihistaminics, leucotrien antagonists and systemic corticosteroids.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Chronic urticaria accounts for up to 75% of patients with urticaria attending dermatology clinics and can persist for many years. Chronic urticaria often causes significant quality of life issues due to pruritus and urticarial lesions resistant to treatment. Patients attending urticaria clinics have a similar impairment of quality of life as those with eczema or those with coronary disease awaiting by pass surgery. A good response to standard treatment with oral H1 receptor antagonists occurs in under 50%. Immunomodulatory or immunosuppression therapy might therefore required in patients with severe refractory chronic urticaria. But these treatments have too many adverse effects and difficulties in their using. In two current reports, three cases of severe chronic urticaria, unresponsive to conventional therapy, with a successful response to antidepressant mirtazapine were presented. Herein we present three cases responding oral mirtazapine, resistant combination therapies including antihistaminics, leucotrien antagonists and systemic corticosteroids.

Özet

Kronik ürtiker, ürtiker şikayeti ile dermatoloji polikliniklerine başvuran hastaların yaklaşık olarak %75’ini oluşturur ve uzun yıllar sebat edebilir. Kronik ürtiker, kaşıntı ve lezyonların tedavilere dirençli olması nedeni ile yaşam kalitesini önemli ölçüde bozar. Kronik ürtiker semptomlarının meydana getirdiği yaşam kalitesi bozukluğu ekzema veya by-pass için bekleyen koroner hastalarınınkine eşdeğerdir. Tedavide kullanılan başlıca ilaçlar antihistaminiklerdir. Ancak oral H1 reseptör antagonistlerinin standart kullanımlarına iyi bir yanıt alınma şansı % 50’nin altındadır. Bu yüzden şiddetli refrakter kronik ürtiker vakalarında, immunsupresif ve immunmodulatör tedaviler gerekebilir. Bu tedaviler belirgin yan etki potansiyeline ve kullanım güçlüğüne sahiptirler. Güncel iki raporda, geleneksel tedavilere dirençli üç kronik ürtiker vakasının, antidepresan bir ilaç olan mirtazapin ile başarılı bir şekilde tedavi edildiği rapor edilmiştir. Burada, antihistaminik, lökotrien antagonistleri ve sistemik kortikosteroidler ile kombinezon tedavilerine dirençli, oral mirtazapine cevap veren üç vaka sunuyoruz.

🔖

Cite This Article

ÇETİŞLİ, A., ÖZBULUT, Ö., KARACA, Ş., KULAÇ, M. (2022). Oral mirtazapine in persistent chronic urticaria. Türkderm-Deri Hastalıkları ve Frengi Arşivi, Cilt: 42 - Sayı: 1, 31–33. https://ajindex.com/articles/622101

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Alonso, L. Urticaria and angioedema, Allergol Immunopathol (Madr). 1999; 27:71-3
  2. Kaya Tİ, Akyol A. Ürtiker patogenezi: Kronik idiopatik ürtiker konusunda geliflmeler. Türkiye Klinikleri Dermatoloji Dergisi. 1999; 9: 41-50
  3. Sukan M, Maner F, Tosun M. Kronik Ürtikerin Psikiyatrik Yönü. Yeni Symposium. 2005; 43: 167-72 4. Humphreys F, Hunter JAA. The characteristics of urticaria in 390 patients. Br J Dermatol. 1998; 138: 635-8
  4. Black AK. Treatment of refractory chronic urticaria. Clin Exp Dermatol. 2000; 25: 154-66
  5. Kaplan AP, Charleston SC. Chronic urticaria: Pathogenesis and treatment. N Engl J Med. 2002; 346: 175-9
  6. Bigata X, Sais G, Soler F. Severe chronic urticaria: Response to mirtazapine. J Am Acad Dermatol. 2005; 53: 916-17
  7. Thormann H, Bindslev-Jensen C. Mirtazapine for chronic urticaria. Acta Derm Venereol. 2004; 84: 475-500
  8. Hollister LE. Antidepressant agents. In: Basic & Clinical Pharmacology. Katzung BG (eds). Appleton & Lange. 1992: 411-19
  9. Tennyson H, Levine L. Neurotropic and psychotropic drugs in dermatology. Dermatol Clin. 2001; 19: 179-97
  10. Bonnel RA, Grenade L, Karwoski CB, Beitz JG. Allergic Contact Dermatitis from topikal doxepin: Food and Drug Administration’s postmarketing surveillance experience. J Am Acad Dermatol. 2003; 48: 294-6
  11. Hundley JL, Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. J Am Acad Dermatol 2004; 50: 889-91.